A pill that’s being developed by Pfizer as a potential cure for COVID-19 could be ready later this year if the trials are successful, a report said.
The antiviral drug, PF-07321332, is designed to attack the “spine” of the SARS-CoV-2 virus to prevent it from replicating in the nose, throat and lungs, the Telegraph reported.
“We have designed PF-07321332 as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalized or in critical care,” Mikael Dolsten, who leads the company’s worldwide research, development and medical division, said in a statement.
#COVID19 #Pfizer
The New York Post is your source for breaking news, news about New York, sports, business, entertainment, opinion, real estate, culture, fashion, and more.
Catch the latest news here: https://nypost.com/
Follow The New York Post on:
Twitter – https://twitter.com/nypost
Facebook – https://www.facebook.com/NYPost